<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04826679</url>
  </required_header>
  <id_info>
    <org_study_id>OBU-GD1-BC-HNC-II-001</org_study_id>
    <nct_id>NCT04826679</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC</brief_title>
  <official_title>An Open Label, Single Arm Phase II Study of Camrelizumab in Combination With Cisplatin and Nab-paclitaxel as a Novel Neoadjuvant Pre-Surgical Therapy for Resectable HNSCC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single arm phase II trial including 53 patients with&#xD;
      T2N2-3M0、T3-4N0-3M0（III-IV） head and neck squamous cell carcinoma (HNSCC) eligible for&#xD;
      resection, who receive neo-adjvuant Camrelizumab combined with cisplatin and Nab-paclitaxel.&#xD;
&#xD;
      This proposed study will evaluate the efficacy and safety of preoperative administration of&#xD;
      Camrelizumab combined with chemotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC) who&#xD;
      are about to undergo surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, eligible subject will be enrolled into study arm to accept study treatment.&#xD;
      Objective response rate will be the primary outcome measures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>9 weeks</time_frame>
    <description>overall response rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pCR</measure>
    <time_frame>9 weeks</time_frame>
    <description>Pathological Complete Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MPR</measure>
    <time_frame>9 weeks</time_frame>
    <description>Major Pathological Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>9 weeks</time_frame>
    <description>Disease Control Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>2 years</time_frame>
    <description>Progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>5 years</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events graded by CTCAE v5.0</measure>
    <time_frame>90 days after the first dose of study treatment</time_frame>
    <description>Percentage of adverse events that are possibly, probably or definitely related to study treatment per Criteria for Adverse Events version 5 (CTCAE v5.0).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">53</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Camrelizumab + Cisplatin + Nab-paclitaxel&#xD;
Camrelizumab (IV), dose= 200mg , day=1 , cycle length: 21 days. Cisplatin (IV), dose=60mg/m2, day= 1, cycle length: 21 days. Nab-paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab, nab-paclitaxel, cisplatin</intervention_name>
    <description>Patients receive Camrelizumab IV on day 1, nab-paclitaxel IV on day 1 and cisplatin IV on day 1.&#xD;
Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Camrelizumab and chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria：&#xD;
&#xD;
          1. Confirmed pathologic and/or cytologic diagnosis of squamous cell carcinoma of head and&#xD;
             neck，T2N2-3M0、T3-4N0-3M0（III-IV）（AJCC 8.0）&#xD;
&#xD;
          2. Greater than or equal to 18 and less than 65 years of age at time of study entry.&#xD;
&#xD;
          3. ECOG performance status of 0 or 1.&#xD;
&#xD;
          4. Resectable or potentially resectable lesion, without distance metastasis;&#xD;
&#xD;
          5. Measurable disease as per RECIST 1.1.&#xD;
&#xD;
          6. Screening labs must meet the following criteria and must be obtained within 14 days&#xD;
             prior to registration:&#xD;
&#xD;
          7. Adequate hepatic、cardiac、brain and renal function as demonstrated by 1) Hematology:&#xD;
             WBC≥4000/μL、NE≥2.000/μL、HGB≥9 g/dL、PLT≥100000/μL； 2) Renal: Serum creatinine &lt; 1.5x&#xD;
             ULN or CrCl &gt; 60mL/min (if using the Cockcroft-Gault formula below): 3) Hepatic: Total&#xD;
             Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total&#xD;
             bilirubin &lt; 3 x ULN)；AST/ALT ≤ 3 x ULN and ALP≤3 x ULN；ALB≥3g / dL；&#xD;
&#xD;
          8. Ability to understand and willingness to sign an IRB approved written informed consent&#xD;
             document. Subject is willing and able to comply with the protocol for the duration of&#xD;
             the study including undergoing treatment and scheduled visits and examinations&#xD;
             including follow up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe allergic reaction to any component of PD-1 monoclonal antibodies or other&#xD;
             monoclonal antibodies.&#xD;
&#xD;
          2. Active, known or suspected autoimmune disease, including dementia and epilepsy.&#xD;
&#xD;
          3. Has had another known invasive malignancy or unresectable cancer.&#xD;
&#xD;
          4. Coagulation dysfunction: (PT &gt; 16S, APTT &gt; 53s, TT &gt; 21s, FIB &lt; 1.5g / L), bleeding&#xD;
             tendency or thrombolysis, anticoagulation treatment.&#xD;
&#xD;
          5. Severe cardiac disease, lung dysfunction, heart function and lung function lower than&#xD;
             grade 3 (≤3).&#xD;
&#xD;
          6. Laboratory abnormality within 7 days before enrollment.&#xD;
&#xD;
          7. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4&#xD;
             antibody, or any other antibody or drug specifically targeting T-cell co-stimulation&#xD;
             or immune checkpoint pathways.&#xD;
&#xD;
          8. Subjects with a condition requiring systemic treatment with either corticosteroids or&#xD;
             other immunosuppressive medications before enrollment.&#xD;
&#xD;
          9. Has a known history of Human Immunodeficiency Virus (HIV).&#xD;
&#xD;
         10. Has a known history of Hepatitis B (defined as HBV DNA ≥1000 cps/mL is detected) or&#xD;
             known active Hepatitis C virus (defined as: HCV antibody positive) infection.&#xD;
&#xD;
         11. have received anti-tumor herbs within 4 weeks before randomization.&#xD;
&#xD;
         12. Pregnant or nursing women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>xuekui Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>xuekui Liu</last_name>
    <phone>13609713406</phone>
    <email>Liuxk@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xuekui Liu</last_name>
      <phone>13609713406</phone>
      <email>Liuxk@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 30, 2021</study_first_submitted>
  <study_first_submitted_qc>March 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Xuekui Liu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

